Tang, Siuwah
(2014)
miR-125 is a Novel Biomarker in Pancreatic Cancer Patients.
Doctoral Dissertation, University of Pittsburgh.
(Unpublished)
This is the latest version of this item.
Abstract
Approximately 46,420 Americans are diagnosed with pancreatic cancer and 39,590 individuals die from the disease annually. Pancreatic cancer is associated with a less than 5% five-year survival rate.1 Early diagnosis is rare and surgical treatment is most beneficial before the cancer becomes locally invasive or metastatic. Previously, we identified in vitro DAMPmiRs (Damage Associated Molecular Pattern molecule induced microRNAs, miR-34c and miR-214) that are differentially expressed in peripheral blood mononuclear cells (PBMCs) upon DAMP stimulation and play an important role in regulating the inflammatory response via targeting inflammatory pathways. DAMPs are passively released into the local micro-environment, and progressively, into the systemic circulation to initiate early innate and adaptive immune responses.2,3 Whether the microRNA (miRNA) expression in pancreatic cancer patients’ PBMC is different from those of normal healthy individuals is unknown. Here, we examined the miRNA expression profile of age and sex matched samples to identify potential miRNA markers. One of the most promising markers (miR-125a-5p) was selected for further analysis in patients enrolled in our recently completed phase I/II pre-operative treatment with hydroxychloroquine and gemcitabine. We also evaluated how individual immunological stimuli affect miR-125a-5p expression in normal PBMC and validated several miR-125a-5p predicted down-stream targets.
Share
| Citation/Export: |
|
| Social Networking: |
|
Details
| Item Type: |
University of Pittsburgh ETD
|
| Status: |
Unpublished |
| Creators/Authors: |
|
| ETD Committee: |
|
| Date: |
19 September 2014 |
| Date Type: |
Publication |
| Defense Date: |
13 June 2014 |
| Approval Date: |
19 September 2014 |
| Submission Date: |
9 July 2014 |
| Access Restriction: |
No restriction; Release the ETD for access worldwide immediately. |
| Number of Pages: |
141 |
| Institution: |
University of Pittsburgh |
| Schools and Programs: |
Swanson School of Engineering > Bioengineering |
| Degree: |
PhD - Doctor of Philosophy |
| Thesis Type: |
Doctoral Dissertation |
| Refereed: |
Yes |
| Uncontrolled Keywords: |
pancreatic adenocarcinoma, gemcitabine, hydroxychloroquine, microRNA, DAMPs (damage associated molecular pattern molecules), HMGB1, CA 19-9, miR125a-5p, tumor immunology, autophagy, neoadjuvant therapy |
| Date Deposited: |
19 Sep 2014 18:22 |
| Last Modified: |
19 Dec 2016 14:41 |
| URI: |
http://d-scholarship.pitt.edu/id/eprint/22285 |
Available Versions of this Item
-
miR-125 is a Novel Biomarker in Pancreatic Cancer Patients. (deposited 19 Sep 2014 18:22)
[Currently Displayed]
Metrics
Monthly Views for the past 3 years
Plum Analytics
Actions (login required)
 |
View Item |
![[feed]](/images/feed-icon-32x32.png){kind=icon}